CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

US9803021B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventor

• Sherie L. Morrison · Los Angeles, US

Key dates

• Filing date: Dec 5, 2013
• Grant date: Oct 31, 2017
• Expiry date: Dec 5, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha.